BACKGROUND: Chronic medical conditions such as opioid dependence require evidence-based treatment recommendations. However, pregnant women are under-represented in clinical trials. We describe the first within-subject comparison of maternal and neonatal outcomes for methadone- versus buprenorphine-exposed pregnancies. Although methadone is the established treatment of pregnant opioid-dependent women, recent investigations have shown a trend for a milder neonatal abstinence syndrome (NAS) under buprenorphine. However, it is not only the choice of maintenance medication that determines the occurrence of NAS; other factors such as maternal metabolism, illicit substance abuse and nicotine consumption also influence its severity and duration and represent confounding factors in the assessment of randomized clinical trials. CASE SERIES DESCRIPTION: Three women who were part of the European cohort of a randomized, double-blind multi-center trial with a contingency management tool [the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study], each had two consecutive pregnancies and were maintained on either methadone or buprenorphine for their first and then the respective opposite, still-blinded medication for their second pregnancy. Birth measurements, the total neonatal abstinence score, the total amounts of medication used to treat NAS and the days of NAS treatment duration were assessed. RESULTS: Both medications were effective and safe in reducing illicit opioid relapse and avoiding preterm labor. Methadone maintenance yielded to a significantly higher neonatal birth weight. Data patterns suggest that buprenorphine exposure was associated with lower neonatal abstinence syndrome (NAS) scores. Findings from this unique case series are consistent with earlier reports using between-group analyses. CONCLUSIONS:Buprenorphine has the potential to become an established treatment alternative to methadone for pregnant opioid-dependent women. Under special consideration of ethical boundaries, psychopharmacological treatment during pregnancy must be addressed as an integral part of clinical research projects in order to optimize treatment for women and neonates.
RCT Entities:
BACKGROUND: Chronic medical conditions such as opioid dependence require evidence-based treatment recommendations. However, pregnant women are under-represented in clinical trials. We describe the first within-subject comparison of maternal and neonatal outcomes for methadone- versus buprenorphine-exposed pregnancies. Although methadone is the established treatment of pregnant opioid-dependent women, recent investigations have shown a trend for a milder neonatal abstinence syndrome (NAS) under buprenorphine. However, it is not only the choice of maintenance medication that determines the occurrence of NAS; other factors such as maternal metabolism, illicit substance abuse and nicotine consumption also influence its severity and duration and represent confounding factors in the assessment of randomized clinical trials. CASE SERIES DESCRIPTION: Three women who were part of the European cohort of a randomized, double-blind multi-center trial with a contingency management tool [the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study], each had two consecutive pregnancies and were maintained on either methadone or buprenorphine for their first and then the respective opposite, still-blinded medication for their second pregnancy. Birth measurements, the total neonatal abstinence score, the total amounts of medication used to treat NAS and the days of NAS treatment duration were assessed. RESULTS: Both medications were effective and safe in reducing illicit opioid relapse and avoiding preterm labor. Methadone maintenance yielded to a significantly higher neonatal birth weight. Data patterns suggest that buprenorphine exposure was associated with lower neonatal abstinence syndrome (NAS) scores. Findings from this unique case series are consistent with earlier reports using between-group analyses. CONCLUSIONS:Buprenorphine has the potential to become an established treatment alternative to methadone for pregnant opioid-dependent women. Under special consideration of ethical boundaries, psychopharmacological treatment during pregnancy must be addressed as an integral part of clinical research projects in order to optimize treatment for women and neonates.
Authors: R E Johnson; H E Jones; D R Jasinski; D S Svikis; N A Haug; L M Jansson; W B Kissin; G Alpan; M E Lantz; E J Cone; D G Wilkins; A S Golden; G R Huggins; B M Lester Journal: Drug Alcohol Depend Date: 2001-06-01 Impact factor: 4.492
Authors: Hendrée E Jones; Cheryl Harrow; Kevin E O'Grady; Michael Crocetti; Lauren M Jansson; Karol Kaltenbach Journal: J Opioid Manag Date: 2010 Nov-Dec
Authors: G Fischer; R E Johnson; H Eder; R Jagsch; A Peternell; M Weninger; M Langer; H N Aschauer Journal: Addiction Date: 2000-02 Impact factor: 6.526
Authors: Robin E Choo; Marilyn A Huestis; Jennifer R Schroeder; Angela S Shin; Hendrée E Jones Journal: Drug Alcohol Depend Date: 2004-09-06 Impact factor: 4.492
Authors: Hendrée E Jones; Sarah H Heil; Andjela Baewert; Amelia M Arria; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Gabriele Fischer Journal: Addiction Date: 2012-11 Impact factor: 6.526
Authors: Bomee Kim; Yun Ji Jang; Hae Ram Cho; So Yeon Kim; Ji Eun Jeong; Mi Kyoung Shim; Myeong Gyu Kim Journal: Clin Transl Sci Date: 2021-11-17 Impact factor: 4.689
Authors: Alex Farr; Herbert Kiss; Michael Hagmann; Iris Holzer; Verena Kueronya; Peter W Husslein; Ljubomir Petricevic Journal: BMC Pregnancy Childbirth Date: 2016-08-05 Impact factor: 3.007